her2 - Robuta Search

https://www.preprints.org/manuscript/202401.0437 HER2 Positive Early Breast Cancer: Time for Ultimate De-escalation?[v1] | Preprints.org De-escalation is currently taking place both in surgical and systemic treatment of breast cancer. The introduction of trastuzumab, the first monoclonal... early breast cancer https://www.mayo.edu/research/clinical-trials/cls-20439962?&p=1 A Vaccine (H2NVAC) Before Surgery For The Treatment Of HER2-Expressing Ductal Carcinoma In Situ -... https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic... On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults... https://www.breastcancer.org/podcast/her2-positive-recurrence HER2-Positive Breast Cancer Recurrence Marleen Meyers, MD talks about HER2-positive disease and specific ways to reduce its risk of recurrence. her2 positive breast cancer recurrence https://www.rti.org/publication/overall-survival-associated-cdk4-6-inhibitors-patients-hr-her2-metastatic-breast-cancer-united-state Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast... BACKGROUND: Evidence on overall survival (OS) with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors is generally limited to data from clinical trials or a... https://www.semanticscholar.org/topic/ex-vivo-expanded-HER2-specific-T-cells/6010602 ex vivo-expanded HER2-specific T cells | Semantic Scholar T cells specific for the human epidermal growth factor receptor 2 (HER2) with potential immunopotentiating activity. T cells directed against HER2,... ex vivo t cells expanded her2 specific https://openreview.net/forum?id=qDEYfzeK7k An interpretable automated detection system for FISH-based HER2 oncogene amplification testing in... We developed a comprehensible deep learning-based pipeline which automates the evaluation of FISH images with respect to HER2 gene amplification testing for... https://www.news-medical.net/news/20241022/New-antibody-targets-cancer-causing-HER2-mutations.aspx New antibody targets cancer-causing HER2 mutations Oct 22, 2024 - For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer. new antibody targets cancer causing https://pmc.ncbi.nlm.nih.gov/articles/PMC7375662/ Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications... Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However,... https://elifesciences.org/articles/85246v1 Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast... https://www.mskcc.org/news/antibody-drug-conjugate-for-endocrine-refractory-and-chemotherapy-naive-er-her2-breast Antibody-Drug Conjugate for Endocrine-Refractory and Chemotherapy Naive HR+, HER2- Breast Cancer |... Read about an antibody-drug conjugate treatment for HR+, HER2- breast cancer. antibody drug conjugate https://www.kth.se/en/om/upptack/kalender/disputationer/targeting-her2-expressing-tumors-with-potent-drug-conjugates-and-fusion-toxins-based-on-scaffold-proteins-1.1188679 Targeting HER2-expressing tumors with potent drug conjugates and fusion toxins based on scaffold... https://www.uab.edu/engineering/home/news-events/soe-news-feed/sorace-receives-r01-from-nci-to-study-immunotherapy-in-her2-breast-cancer-through-imaging Sorace receives R01 from NCI to study immunotherapy in HER2+ breast cancer through Imaging | School... The UAB School of Engineering is a world-class institution of engineering education and research, consisting of 5 departments within a major research... https://pmc.ncbi.nlm.nih.gov/articles/PMC6536781/ Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line... The highly tunable, noninvasive and spatially targeted nature of microbubble-enhanced, ultrasound-guided (MB+US) drug delivery makes it desirable for a wide... https://www.intel.com/content/www/us/en/docs/onemkl/developer-reference-c/2025-2/p-her2.html p?her2 Performs a rank-2 update of a distributed Hermitian matrix. p her2 https://www.mdpi.com/2077-0383/12/6/2121 Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast... Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality affecting life expectancy amongst cancer survivors. In recent years,... side effects https://www.prnewswire.com/news-releases/phrontline-biopharma-presents-preclinical-data-for-tj106-a-biparatopic-her2-dual-payload-adc-at-american-association-for-cancer-research-annual-meeting-2026-302741543.html Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at... /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting... https://www.esmo.org/oncology-news/fda-approves-pembrolizumab-for-her2-positive-gastric-or-gastro-oesophageal-junction-adenocarcinoma-expressing-pd-l1-cps-1 FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... gastro oesophageal junction her2 positive https://www.mskcc.org/cancer-care/clinical-trials/24-282 A Phase 2 Study of Zongertinib in People With HER2-Positive Advanced Solid Tumors | Memorial Sloan... Full Title Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-Label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-her2-adc-bb-1701 Definition of anti-HER2 ADC BB-1701 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of anti her2 adc bb https://www.hmpgloballearningnetwork.com/site/onc/news/anbenitamab-plus-chemotherapy-significantly-improves-survival-previously-treated-her2 Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive... Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously... plus chemotherapy significantly improves https://elifesciences.org/reviewed-preprints/92873v1/reviews Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth... https://pmc.ncbi.nlm.nih.gov/articles/PMC6449170/ Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-... Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was assessed separately for three PALOMA studies. This... https://elifesciences.org/reviewed-preprints/103953v2/reviews Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2... cysteine metabolism for the https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-everolimus-letrozole-exemestane-advanced-her2-negative-breast-cancer-bolero-4 A trial of everolimus, letrozole and exemestane for advanced HER2 negative breast cancer (BOLERO 4) This trial looked at adding everolimus to letrozole and exemestane for breast cancer. https://www.esmo.org/oncology-news/trastuzumab-deruxtecan-prolongs-os-in-second-line-treatment-for-patients-with-her2-positive-metastatic-gastric-or-gej-adenocarcinoma Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... second line treatment https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast?ref=onyxnewsroom.com FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic... On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults... https://www.aacr.org/about-the-aacr/newsroom/news-releases/her2-targeted-car-t-cell-therapy-safe-with-promising-antitumor-activity-in-patients-with-advanced-sarcoma/ HER2-targeted CAR T-cell Therapy Safe, With Promising Antitumor Activity in Patients With Advanced... Dec 2, 2019 - HER2-targeted CAR T-cell Therapy Safe, With Promising Antitumor Activity in Patients With Advanced Sarcoma car t cell therapy https://www.gene.com/media/news-features/perjeta-approved-for-her2-positive-metastatic-breast-cancer Genentech: News Features | Perjeta Approved For HER2-Positive Metastatic Breast Cancer Access media kits and related information for our featured news stories. news features her2 positive genentech perjeta approved https://www.aacr.org/about-the-aacr/newsroom/news-releases/hr-positive-her2-negative-breast-cancer-patients-with-high-risk-of-recurrence-may-benefit-from-addition-of-anthracyclines-to-taxane-based-chemotherapy/ HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From... Dec 13, 2024 - Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of anthracyclines... her2 negative breast cancer https://www.breastcancer.org/research-news/kadcyla-improves-survival-for-some-mets-dx Kadcyla Improves Survival in Women Diagnosed With Metastatic, HER2-Positive Disease That's Stopped... The TH3RESA study found that Kadcyla improved overall survival in women diagnosed with metastatic, HER2-positive breast cancer that had stopped responding to... https://www.biospace.com/press-releases/tharimmune-announces-positive-data-with-novel-biparatopic-pd-1-vegf-and-multispecific-her2-her3-biologics-leveraging-proprietary-epiclicktm-technology Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3... https://www.aacr.org/about-the-aacr/newsroom/news-releases/new-her2-antibody-drug-conjugate-yielded-promising-clinical-responses-in-breast-cancer-patients-pretreated-with-t-dm1/ New HER2 Antibody-drug | AACR News Releases Dec 26, 2019 - New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1 new her2 antibody drug aacr https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-11062 Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain... Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain Metastasis her2 negative breast cancer https://www.mdanderson.org/newsroom/sabcs-combining-ribociclib-hormone-therapy-improved-patient-outcomes-early-stage-breast-cancer.h00-159624168.html Patients with HR+/HER2- early-stage breast cancer see improved outcomes when treated with... Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease-free survival (iDFS) benefits in patients with early-stage... https://www.preprints.org/manuscript/201902.0043 HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer[v1] | Preprints.org Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2... https://www.rcsb.org/structure/6D8E RCSB PDB - 6D8E: Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion... Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitor https://www.preprints.org/manuscript/202410.0856 Preclinical Pharmacokinetics studies of SPH5030, a Novel, Selective, Potent, and Irreversible HER2... SPH5030 is developed to improve the selectivity of irreversible HER2 inhibitors, which shows excellent activity and better HER2 selectivity against four common... preclinical pharmacokinetics https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-buparlisib-with-paclitaxel-for-advanced-her2-negative-breast-cancer-belle4 A trial of buparlisib and paclitaxel for advanced HER2 negative breast cancer (BELLE 4) This trial looked at adding buparlisib to paclitaxel for breast cancer that is HER2 negative. her2 negative breast cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/ Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer - PMC Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of... advanced breast cancer trastuzumab deruxtecan previously treated https://www.mskcc.org/news/new-drug-combination-for-er-her2-breast-cancer-may-improve-outcomes New Drug Combination Improves Survival for ER+, HER2- Breast Cancer | Memorial Sloan Kettering... Learn about a three-drug treatment that has been shown to extend survival for ER+, HER2- breast cancers. https://www.esmo.org/meeting-calendar/esmo-congress-2025/industry-sponsored-satellite-symposia/expanding-the-frontiers-of-her2-targeted-therapy-in-gynecologic-cancers Expanding the Frontiers of HER2-Targeted Therapy in Gynecologic Cancers | ESMO the frontiers targeted therapy gynecologic cancers expanding her2 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic... FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://www.intel.com/content/www/us/en/docs/onemkl/developer-reference-c/2024-1/cblas-her2.html cblas_?her2 Performs a rank-2 update of a Hermitian matrix. cblas her2 https://www.cancer.gov/news-events/cancer-currents-blog/2021/enhertu-her2-metastatic-breast-cancer Enhertu Effective in HER2-Positive Metastatic Breast Cancer - NCI In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival... metastatic breast cancer her2 positive enhertu effective nci https://www.biospace.com/initial-phase-1-dose-escalation-data-of-oric-114-in-patients-with-egfr-and-her2-exon-20-mutations-demonstrates-potential-best-in-class-profile Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations... Oct 23, 2023 - ORIC Pharmaceuticals, Inc. announced initial data from the ongoing ORIC-114 Phase 1 dose escalation trial for patients with EGFR or HER2 exon 20 mutated... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-her2-her3-monoclonal-antibody-mixture-sym013 Definition of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.preprints.org/manuscript/202210.0028 Antitumor Activity of an anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine... The overexpression of epidermal growth factor receptors (EGFRs) has been reported in various human tumors, including breast, gastric, lung, colorectal, and... https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1099545/full Frontiers | Cardiovascular adverse effects associated with the use of anti-HER2 in breast cancer... Background: Cancer represents an important public health problem with increasing incidence, prevalence, and mortality, affecting the entire Western populatio... https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report Metastatic HR+/HER2 Metastatic Breast Cancer Market Size 2026 Global Metastatic HR+/HER2? Breast Cancer market size is expected to reach $17.26 billion by 2030 at 9.6%, increasing demand for hormone replacement therapy... breast cancer market size metastatic hr her2 https://www.mdanderson.org/newsroom/archived-news/study-finds-no-difference-in-disease-free-overall-survival-for-HER2-breast-cancer-patients-receiving-treatment-concurrently-or-sequentially.h00-159227301.html ARCHIVED: Study finds no difference in overall survival for HER2+ breast cancer patients receiving... New research in women with HER2+ breast cancer found no difference in disease-free survival (DFS) and overall survival (OS) when receiving anthracycline-based... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-00701&r=1 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer - NCI (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer https://www.biospace.com/puma-biotechnology-announces-phase-ii-clinical-trial-design-for-alisertib-in-her2-negative-hormone-receptor-positive-metastatic-breast-cancer Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone... Dec 11, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment... phase ii clinical trial https://www.preprints.org/manuscript/201701.0098 Induction of G2M Arrest by Flavokawain A, A Kava Chalcone, Increases the Responsiveness of HER2... HER2/neu positive breast tumors predict a high mortality and comprise 25-30% of breast cancer. We have shown that Flavokawain A (FKA) preferentially reduces... https://www.breastcancer.org/research-news/2-studies-confirm-kadcylas-benefits Final Results From Two Studies Confirm Kadcyla's Benefits for Advanced-Stage HER2-Positive Disease Final results from the EMILIA and TH3RESA studies show that Kadcyla improves overall survival in people diagnosed with advanced-stage HER2-positive breast... https://cancer.ca/en/treatments/tests-and-procedures/her2-status-test HER2 status test | Canadian Cancer Society Knowing the HER2 status of a tumour helps your healthcare team plan the type of treatment to give you. her2 status test canadian cancer https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302582286.html Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC... /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically... https://www.news-medical.net/news/20220830/Leukemia-drug-successfully-disrupts-HER2-positive-brain-metastasis-in-animal-studies.aspx Leukemia drug successfully disrupts HER2-positive brain metastasis in animal studies Aug 30, 2022 - In animal studies led by researchers at Duke Cancer Institute, a drug approved to treat leukemia successfully disrupted the ability of HER2-positive breast... her2 positive brain metastasis leukemia drug successfully https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-09124 Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable,... Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable, Locally Advanced or Metastatic Breast Cancer datopotamab deruxtecan for the her2 negative trastuzumab https://www.cancer.gov/news-events/cancer-currents-blog/2017/trastuzumab-emtansine-breast-cancer Trastuzumab Emtansine for HER2-Positive Breast Cancer - NCI An NCI Cancer Currents blog on results from the TH3RESA and EMILIA clinical trials showing trastuzumab emtansine (T-DM1) improved overall survival in patients... her2 positive breast cancer trastuzumab emtansine nci https://www.sciencedaily.com/releases/2010/12/101210091103.htm Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer... The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study... https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2 Definition of HER2 - NCI Dictionary of Cancer Terms - NCI NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. definition of her2 nci dictionary cancer https://www.rcsb.org/structure/3PP0 RCSB PDB - 3PP0: Crystal Structure of the Kinase domain of Human HER2 (erbB2). Crystal Structure of the Kinase domain of Human HER2 (erbB2). rcsb pdb crystal structure of the https://www.her2statusmatters.com/ HER2 Status Matters her2 status matters https://www.doccheck.com/de/profile/channels/1042-onko-mit-her2 Onko mit HER2 - DocCheck Hand aufs Herz: Wie gut kennen Sie HER2? Auf diesem Kanal dreht sich alles rund um den HER2-Status bei fortgeschrittenem Lungen-, Brust- und Magenkrebs. Hier... onko mit her2 doccheck https://www.businesswire.com/news/home/20240814155176/en/Accutar-Biotechnology-Receives-FDA-Fast-Track-Designation-for-AC699-in-ER-HER2--Breast-Cancer Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced today that the US Food and Dr... https://www.henryford.com/blog/2022/10/her2-breast-cancer-treatments FDA Approves First Drug To Treat HER2-Low Breast Cancer | Henry Ford Health - Detroit, MI HER2-Low breast cancer used to be hard to treat. But a new drug--which combines chemotherapy with monoclonal antibody treatment--is changing that. https://www.acc.org/Latest-in-Cardiology/Articles/2022/05/23/13/25/Cardiotoxicity-and-the-Evolving-Landscape-of-HER2-Targeted-Breast-Cancer-Treatment Cardiotoxicity and the Evolving Landscape of HER2-Targeted Breast Cancer Treatment - American... breast cancer treatment https://www.biospace.com/os-therapies-acquires-all-indications-for-ost-her2-listeria-monocytogenes-in-solid-tumors-including-canines OS Therapies Acquires All Indications for OST-HER2 (Listeria monocytogenes) in Solid Tumors,... Nov 17, 2020 - OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and... https://www.breastcancer.org/podcast/kisqali-monaleesa-2 Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative... Dr. Gabriel Hortobagyi discusses overall survival results from the MONALEESA-2 trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC4143557/ Computational analyses of curcuminoid analogs against kinase domain of HER2 - PMC Human epidermal growth factor receptor 2 (HER2) has an important role in cancer aggressiveness and poor prognosis. HER2 has been used as a drug target for... computational analyses curcuminoid analogs kinase https://elifesciences.org/reviewed-preprints/92873v1 Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth... https://stanfordhealthcare.org/trials/p/NCT03241810.html Phase II Seribantumab + Fulvestrant in Hormone Receptor+, Heregulin+, HER2- Metastatic Breast Cancer Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more. phase ii hormone receptor https://www.breastcancer.org/research-news/herceptin-plus-tykerb-no-better-than-alone Herceptin Plus Tykerb After Surgery No Better Than Herceptin Alone for Early-Stage, HER2-Positive... Women diagnosed with early-stage, HER2-positive breast cancer treated with both Herceptin and Tykerb after surgery had the same disease-free survival as women... https://www.nice.org.uk/guidance/TA1153 Overview | Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more... Evidence-based recommendations on zanidatamab (Ziihera) for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment in... https://www.fiercebiotech.com/medtech/asco-her2-diagnostics-need-revolution-astrazeneca-daiichis-enhertu-looks-redefine-breast ASCO: HER2 diagnostics need a revolution after Enhertu data Jun 6, 2022 - Pathologists have a hard time distinguishing between IHC 0 and IHC 1+ HER2 expression on existing assays, Debu Tripathy, M.D., at MD Anderson said. asco her2 diagnostics need revolution https://www.gsk.com/en-gb/media/press-releases/phase-iii-study-in-her2-positive-advanced-breast-cancer-shows-overall-survival-benefit-when-tykerb-is-combined-with-paclitaxel/ Phase III study in HER2-positive advanced breast cancer shows overall survival benefit when Tykerb... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1473620/full Frontiers | A case report of HER2-positive descending colon cancer with peritoneal metastasis and... Human epidermal growth factor receptor 2 (HER2) is an anti-cancer drug target for colon cancer. Among patients with colorectal malignancy (colorectal cancer,... https://elifesciences.org/articles/92873v1 Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth... Cryo-EM structures uncover glycosylation in the ectodomains of full-length HER4 homodimer and HER2/HER4 heterodimer complexes, revealing how the binding of... https://www.spandidos-publications.com/10.3892/ijo.2015.3277 Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cells International Journal of Oncology is an international journal devoted to oncology research and cancer treatment. breast cancer methylsulfonylmethane her2 expression stat5b https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-buparalisib-for-advanced-breast-cancer-that-is-hormone-receptor-positive-and-her2-negative-belle2 A trial of buparlisib for advanced breast cancer that is hormone receptor positive and HER2... This trial looked at a drug called buparlisib for breast cancer that had spread into tissue surrounding the breast or elsewhere in the body. https://stanfordhealthcare.org/trials/p/NCT02401347.html Phase II Talazoparib in BRCA1 + BRCA2 Wild Type or Triple-Neg or HER2-Neg Breast Cancer/Solid Tumors Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more. https://www.mdanderson.org/cancerwise/her2-positive-breast-cancer-survivor--i-believe-in-md-anderson.h00-159303045.html HER2-positive breast cancer survivor: I believe in MD Anderson | UT MD Anderson Jennifer Smith didn't come to MD Anderson first for her HER2-positive breast cancer treatment, but she wishes she had. her2 positive breast cancer believe in md anderson survivor https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-her2-bispecific-antibody-km257 Definition of anti-HER2 bispecific antibody KM257 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of bispecific antibody her2 nci drug https://www.mountsinai.org/clinical-trials/study-of-xmt-2056-in-advanced-recurrent-solid-tumors-that-express-her2 A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Mount Sinai - New York https://www.medicaldaily.com/herceptin-tyverb-her2-positive-breast-cancer-378099 Drug Combination Of Herceptin And Tyverb Obliterate HER2 Positive Breast Cancer Tumors In 11 Days Mar 16, 2016 - At a recent conference, researchers from the Institute of Cancer Research in London explain how a drug combination worked to dramatically shrink cancer tumors... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2026-01854&r=1 A Study Using ctDNA to Guide Treatment for People with HER2-positive Breast Cancer, HERizon-Breast... A Study Using ctDNA to Guide Treatment for People with HER2-positive Breast Cancer, HERizon-Breast Trial https://www.breastcancer.org/research-news/tx-regimens-before-surgery-to-omit-chemo Can Treatment Regimens Before Surgery for Early-Stage HER2-Positive Breast Cancer Omit Chemotherapy? Treatment before surgery with chemotherapy, Herceptin, and Perjeta seems to be more effective than the combination of Kadcyla and Perjeta before surgery. her2 positive breast cancer https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1086480/full Frontiers | Evolution and clinical significance of HER2-low status after neoadjuvant therapy for... Abstract Background The emergence of HER2 antibody-drug conjugates provides new treatment decisions for breast cancer patients, especially those with HER2-lo... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.669393/full Frontiers | A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in... Breast cancer is the most common malignant cancer in women worldwide, especially in developing countries. Herceptin is a monoclonal antibody with an antitumo... a novel https://www.herconnection.com/ HER2-Positive Breast Cancer Support | HERConnection her2 positive breast cancer support https://www.esmo.org/meeting-calendar/esmo-breast-cancer-2023/industry-sponsored-satellite-symposia/perspectives-on-the-treatment-of-her2-negative-gbrcam-early-breast-cancer Perspectives on the Treatment of HER2-Negative gBRCAm Early Breast Cancer | ESMO early breast cancer on the her2 negative https://www.upmc.com/conditions/h/her2-negative-breast-cancer HER2-Negative Breast Cancer: Causes, Symptoms, and Treatments HER2-negative (HER2-) breast cancer, a type of breast cancer diagnosed when the cancer cells lack HER2 proteins. Find treatment options with UPMC. her2 negative breast cancer causes symptoms treatments https://www.phesgo-hcp.com/ PHESGO for HER2+ Breast Cancer Treatment | (pertuzumab / trastuzumab / hyaluronidase-zzxf) Learn about PHESGO, a subcutaneous injection for HER2+ breast cancer combining PERJETA (pertuzumab) and Herceptin (trastuzumab) that's given in minutes. See... breast cancer treatment pertuzumab trastuzumab phesgo her2 hyaluronidase https://www.hmpgloballearningnetwork.com/site/jcp/videos/hr-positive-and-her2-negative-breast-cancer-treatment-updates HR-Positive and HER2-Negative Breast Cancer Treatment Updates William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor... her2 negative breast cancer hr positive treatment updates https://www.researchandmarkets.com/reports/6115141/her2-negative-breast-cancer-epidemiology-forecast HER2-Negative Breast Cancer: Epidemiology Forecast to 2034 Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates... her2 negative breast cancer epidemiology forecast 2034 https://www.mskcc.org/news-releases/asco-2022-practice-changing-findings-identify-her2-low-targetable-subset-breast-cancer-redefining-treatment-more-60-percent-her2-negative-metastatic-breast-cancer-patients ASCO 2022: Practice-Changing Findings Identify HER2-Low as a Targetable Subset of Breast Cancer,... New data from researchers at MSK featured in the 2022 ASCO Annual Meeting press program and simultaneously published in The New England Journal of Medicine... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01608/full Frontiers | The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem... Background: Deregulation of HER2 expression could affect the biological characteristics of gastric cancer cells and treatment option for gastric cancer patie... https://www.prnewswire.com/apac/news-releases/alphamab-oncology-announced-anti-her2-bispecific-adc-jskn003-received-approval-from-cde-to-initiate-a-phase-iii-clinical-study-for-ovarian-cancer-302340070.html Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate... /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from... https://www.jci.org/articles/view/199043/pdf JCI - HER2 deficiency causes a developmental disorder with growth retardation and craniofacial... developmental disorder